Abstract
The generation of functional human cardiomyocytes carries the potential of replacing damaged, malformed, or congenitally absent cardiac tissue as a definitive cure for cardiac disease. Furthermore, patient-specific cardiomyocytes may yield useful in vitro models of heart tissue for disease investigation, drug development and personalized therapy evaluation. This field has experienced rapid advances in the past few years. Nearly pure populations of cardiomyocytes have been generated from human pluripotent stem cells and new strategies to generate cardiomyocytes from somatic cells have been introduced. Here we review the latest breakthroughs in cardiomyocyte differentiation from human pluripotent stem cells and the creation of cardiomyocytes by direct reprogramming strategies, as well as discuss their limitations.
Keywords: Cardiomyocyte, cardiac differentiation, direct reprogramming, pluripotent stem cells, microRNA, forward programming.
Current Pharmaceutical Design
Title:Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Volume: 20 Issue: 12
Author(s): Chani Hodonsky, Kaihong Wu, Lakshmi Mundada and Ming-Sing Si
Affiliation:
Keywords: Cardiomyocyte, cardiac differentiation, direct reprogramming, pluripotent stem cells, microRNA, forward programming.
Abstract: The generation of functional human cardiomyocytes carries the potential of replacing damaged, malformed, or congenitally absent cardiac tissue as a definitive cure for cardiac disease. Furthermore, patient-specific cardiomyocytes may yield useful in vitro models of heart tissue for disease investigation, drug development and personalized therapy evaluation. This field has experienced rapid advances in the past few years. Nearly pure populations of cardiomyocytes have been generated from human pluripotent stem cells and new strategies to generate cardiomyocytes from somatic cells have been introduced. Here we review the latest breakthroughs in cardiomyocyte differentiation from human pluripotent stem cells and the creation of cardiomyocytes by direct reprogramming strategies, as well as discuss their limitations.
Export Options
About this article
Cite this article as:
Hodonsky Chani, Wu Kaihong, Mundada Lakshmi and Si Ming-Sing, Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990448
DOI https://dx.doi.org/10.2174/13816128113199990448 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Human Cardiac Ryanodine Receptor: Preparation, Crystallization and Preliminary X-ray Analysis of the N-terminal Region
Protein & Peptide Letters Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins
Current Molecular Medicine How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics